Latest Conference Articles

 Oral Anticancer Agent Influence on Adherence in Patients With Multiple Myeloma, Chronic Conditions

Oral Anticancer Agent Influence on Adherence in Patients With Multiple Myeloma, Chronic Conditions

June 6th 2021

ASCO

A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.

ASCO 2021: HOPA Survey Reports Impact of Cancer Drug Shortages

ASCO 2021: HOPA Survey Reports Impact of Cancer Drug Shortages

June 6th 2021

ASCO

A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.

Survival Rates for CLL Improved With Advent of Oral Targeted Therapies

Survival Rates for CLL Improved With Advent of Oral Targeted Therapies

June 5th 2021

ASCO

A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.

Pharmacist-Driven Biosimilar Adoption Model Leads to Cost Savings

Pharmacist-Driven Biosimilar Adoption Model Leads to Cost Savings

June 5th 2021

ASCO

A community oncology practice implemented a team-based approach to utilizing biosimilars.

ASCO 2021: PARP Inhibitor Improves Disease-Free Survival in High-Risk Early Breast Cancer

ASCO 2021: PARP Inhibitor Improves Disease-Free Survival in High-Risk Early Breast Cancer

June 4th 2021

ASCO

Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.

Does Flu Vaccination Affect Risk of Immune-Related Adverse Events from Specific Immune Checkpoint Inhibitors?

Does Flu Vaccination Affect Risk of Immune-Related Adverse Events from Specific Immune Checkpoint Inhibitors?

June 4th 2021

ASCO

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

Tislelizumab Improves Overall Survival in Certain Types of Esophageal Cancer

Tislelizumab Improves Overall Survival in Certain Types of Esophageal Cancer

June 4th 2021

ASCO

Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.

Combo Immunotherapy Regimen Significantly Improves Progression-Free Survival in Advanced Melanoma

Combo Immunotherapy Regimen Significantly Improves Progression-Free Survival in Advanced Melanoma

June 4th 2021

ASCO

Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.

Boost Revenue and Patient Satisfaction With Point-of-Care Testing

Boost Revenue and Patient Satisfaction With Point-of-Care Testing

May 25th 2021

PDS Super-Conference

In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.

CBD for Women’s Health: A Profit Opportunity for Pharmacies

CBD for Women’s Health: A Profit Opportunity for Pharmacies

May 25th 2021

Pharmacy Profit Summit

OTC CBD is often touted for its uses in pain management, anxiety relief, and sleep. But the popular cannabinoid has been shown to benefit women’s health, too––an opportunity that pharmacies can leverage as a cash-based revenue strategy.